

Accretive Health, Inc.
Form 4
February 12, 2016

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
FLANAGAN JOSEPH GERARD

(Last) (First) (Middle)

C/O ACCRETIVE HEALTH,
INC., 401 N. MICHIGAN
AVENUE, SUITE 2700

(Street)

CHICAGO, IL 60611

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Accretive Health, Inc. [ACHI]

3. Date of Earliest Transaction
(Month/Day/Year)
07/03/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner
X Officer (give title below) ___ Other (specify below)
Chief Operating Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
X Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock	02/10/2016		F	(A) or (D) D	\$ 4,026 2.43	(2) (3)	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Accretive Health, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
--------------------------------------------	--------------------------------------------------------	--------------------------------------	----------------------------------------------------	--------------------------------	-----------------------------------------------------------------------------------------	----------------------------------------------------------	---------------------------------------------------------------	--------------------------------------------	----------------------------------------------------

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
FLANAGAN JOSEPH GERARD C/O ACCRETIVE HEALTH, INC. 401 N. MICHIGAN AVENUE, SUITE 2700 CHICAGO, IL 60611			Chief Operating Officer	

Signatures

/s/ Daniel A Zaccardo, 02/12/2016
Attorney-in-Fact

__Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents a reduction of shares to satisfy the tax withholding obligations of the Issuer with respect to the vesting of restricted common stock held by the Reporting Person.
As reported by the Reporting Person on Form 4s dated June 3, 2013, July 9, 2015 and December 31, 2015, the Reporting Person received grants aggregating to 1,484,714 shares of restricted common stock that each vest monthly in equal installments. This number reflects the reduction of an aggregate of 125,633 shares of common stock that were used to satisfy monthly tax withholding obligations as a result of the monthly vesting of the restricted common stock held by the Reporting Person since July 3, 2013 and for which Form 4s were inadvertently not filed with respect to the monthly withholding only.
- (3) In connection therewith, 6,032 shares of common stock were used to satisfy tax withholding at prices ranging from \$1.00 to \$1.99, 31,774 shares of common stock were used to satisfy tax withholding at prices ranging from \$2.00 to \$2.99, 6,474 shares of common stock were used to satisfy tax withholding at prices ranging from \$3.00 to \$3.99, 23,858 shares of common stock were used to satisfy tax withholding at prices ranging from \$5.00 to \$5.99, 5,903 shares of common stock were used to satisfy tax withholding at prices ranging from \$6.00 to \$6.99, 12,386 shares of common stock were used to satisfy tax withholding at prices ranging from \$7.00 to \$7.99, 24,631 shares of common stock were used to satisfy tax withholding at prices ranging from \$8.00 to \$8.99, 8,740 shares of common stock were used to satisfy tax withholding at prices ranging from \$9.00 to \$9.99 and 5,835 shares of common stock were used to satisfy tax withholding at prices ranging from \$10.00 to \$10.99.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.